Therapeutic targets in triple negative breast cancer (Q38084287)

28 August 2017

title

Therapeutic targets in triple negative breast cancer (English)

1 reference

28 August 2017

1 reference

Sandra A O'Toole

1

1 reference

28 August 2017

Jane M Beith

2

1 reference

28 August 2017

Ewan K A Millar

3

1 reference

28 August 2017

Richard West

4

1 reference

28 August 2017

Anna McLean

5

1 reference

28 August 2017

Aurelie Cazet

6

1 reference

28 August 2017

Alexander Swarbrick

7

1 reference

28 August 2017

Samantha R Oakes

8

1 reference

28 August 2017

language of work or name

English

0 references

publication date

22 February 2013

1 reference

Journal of Clinical Pathology

28 August 2017

published in

1 reference

28 August 2017

volume

66

1 reference

28 August 2017

issue

6

1 reference

28 August 2017

page(s)

530-542

1 reference

Treatment of HER2-positive breast cancer: current status and future perspectives.

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Breast cancer molecular profiling with single sample predictors: a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Triple negative breast cancer: outcome correlation with immunohistochemical detection of basal markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Triple-Negative Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Molecular classification and molecular forecasting of breast cancer: ready for clinical application?

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Triple-negative breast cancer: clinical features and patterns of recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Metastatic behavior of breast cancer subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Impact of triple-negative breast cancer phenotype on prognosis in patients with stage I breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Poly(ADP-ribose) polymerase inhibition: a new direction for BRCAand triple-negative breast cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

DNA repair signature is associated with anthracycline response in triple negative breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Triple-negative breast cancer: role of the androgen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Identification of molecular apocrine breast tumours by microarray analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Comprehensive molecular portraits of human breast tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Prognostic interaction between expression of p53 and estrogen receptor in patients with node-negative breast cancer: results from IBCSG Trials VIII and IX

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Sequence analysis of mutations and translocations across breast cancer subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Preoperative weekly cisplatin-epirubicin-paclitaxel with G-CSF support in triple-negative large operable breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Hallmarks of 'BRCAness' in sporadic cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Haematologic toxicities associated with the addition of bevacizumab in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Congestive heart failure risk in patients with breast cancer treated with bevacizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Mutations in the epidermal growth factor receptor (EGFR) gene in triple negative breast cancer: possible implications for targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Lack of EGFR-activating mutations in European patients with triple-negative breast cancer could emphasise geographic and ethnic variations in breast cancer mutation profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Rare oncogenic mutations of predictive markers for targeted therapy in triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Invasive ductal carcinoma of the breast with the "triple-negative" phenotype: prognostic implications of EGFR immunoreactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Oncogenic PI3K deregulates transcription and translation

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Phosphatase and tensin homologue deleted on chromosome 10 deficiency accelerates tumor induction in a mouse model of ErbB-2 mammary tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Phosphatidylinositol 3-kinase pathway activation in breast cancer brain metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Efficacy of everolimus, a novel mTOR inhibitor, against basal-like triple-negative breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

The Hedgehog signalling pathway as a therapeutic target in early breast cancer development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

A paracrine requirement for hedgehog signalling in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Hedgehog signaling in animal development: paradigms and principles

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Hedgehog overexpression is associated with stromal interactions and predicts for poor outcome in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Increased vascularity and spontaneous metastasis of breast cancer by hedgehog signaling mediated upregulation of cyr61

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

The Drosophila homolog of the mouse mammary oncogene int-1 is identical to the segment polarity gene wingless

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Wnt proteins are self-renewal factors for mammary stem cells and promote their long-term expansion in culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Convergence of Wnt, beta-catenin, and cadherin pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Dishevelled activates JNK and discriminates between JNK pathways in planar polarity and wingless signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

A frizzled homolog functions in a vertebrate Wnt signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

dishevelled and armadillo act in the wingless signalling pathway in Drosophila

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Developmental pathways in breast cancer and breast tumor-initiating cells: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Regulation of LEF-1/TCF transcription factors by Wnt and other signals

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Wnt/beta-catenin signaling in development and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

β-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Genetic changes of Wnt pathway genes are common events in metaplastic carcinomas of the breast

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

β-catenin/Wnt signalling pathway in fibromatosis, metaplastic carcinomas and phyllodes tumours of the breast

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Wnt/beta-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Prospective identification of tumorigenic breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

FZD7 has a critical role in cell proliferation in triple negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Evidence that transgenes encoding components of the Wnt signaling pathway preferentially induce mammary cancers from progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Increased Wnt signaling triggers oncogenic conversion of human breast epithelial cells by a Notch-dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Targeted activation of beta-catenin signaling in basal mammary epithelial cells affects mammary development and leads to hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

The soluble wnt receptor Frizzled8CRD-hFc inhibits the growth of teratocarcinomas in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

The canonical Notch signaling pathway: unfolding the activation mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

A novel proteolytic cleavage involved in Notch signaling: the role of the disintegrin-metalloprotease TACE

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Nicastrin functions as a gamma-secretase-substrate receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

The molecular logic of Notch signaling--a structural and biochemical perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

More complicated than it looks: assembly of Notch pathway transcription complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

HES and HERP families: multiple effectors of the Notch signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Notch1-induced mammary tumor development is cyclin D1-dependent and correlates with expansion of pre-malignant multipotent duct-limited progenitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Notch, Myc and breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Opposite effects of Notch-1 and Notch-2 on mesothelioma cell survival under hypoxia are exerted through the Akt pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

The Anti-apoptotic Effect of Notch-1 Requires p56 -dependent, Akt/PKB-mediated Signaling in T Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

High Notch1 protein expression is an early event in breast cancer development and is associated with the HER-2 molecular subtype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Gene expression, molecular class changes, and pathway analysis after neoadjuvant systemic therapy for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Characteristic genes in luminal subtype breast tumors with CD44 CD24-/low gene expression signature

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Tumour stem cells and drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Loss of negative regulation by Numb over Notch is relevant to human breast carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Numb protein expression correlates with a basal-like phenotype and cancer stem cell markers in primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Preclinical profile of a potent gamma-secretase inhibitor targeting notch signaling with in vivo efficacy and pharmacodynamic properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Inhibition of gamma-secretase induces G2/M arrest and triggers apoptosis in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Biomarker and pharmacologic evaluation of the γ-secretase inhibitor PF-03084014 in breast cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Nicastrin regulates breast cancer stem cell properties and tumor growth in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Notch1 inhibition alters the CD44hi/CD24lo population and reduces the formation of brain metastases from breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

A Monoclonal Antibody against Human Notch1 Ligand–Binding Domain Depletes Subpopulation of Putative Breast Cancer Stem–like Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Direct inhibition of the NOTCH transcription factor complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Metalloprotease-disintegrin ADAM12 expression is regulated by Notch signaling via microRNA-29.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

An essential role of metalloprotease-disintegrin ADAM12 in triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

γ-Secretase inhibition promotes cell death, Noxa upregulation, and sensitization to BH3 mimetic ABT-737 in human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Notch Signaling Pathway as a Therapeutic Target in Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

The CBF1-independent Notch1 signal pathway activates human c-myc expression partially via transcription factor YY1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Hallmarks of Cancer: The Next Generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

The Bcl-2 apoptotic switch in cancer development and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Targeting death and decoy receptors of the tumour-necrosis factor superfamily

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Targeting death-inducing receptors in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

TRAIL receptor signaling and therapeutics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Basal-like breast cancer stem cells are sensitive to anti-DR5 mediated cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Effect of anti-DR5 and chemotherapy on basal-like breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

The Bcl-2 protein family: arbiters of cell survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Targeting IAPs as An Approach to Anti-Cancer Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

The Bcl2 family: regulators of the cellular life-or-death switch

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Keeping killers on a tight leash: transcriptional and post-translational control of the pro-apoptotic activity of BH3-only proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Characterization of Stat5a and Stat5b Homodimers and Heterodimers and Their Association with the Glucocortiocoid Receptor in Mammary Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Prognostic influence of BCL2 expression in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Mimicking the BH3 domain to kill cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Phase I/II study of G3139 (Bcl-2 antisense oligonucleotide) in combination with doxorubicin and docetaxel in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Rational design and real time, in-cell detection of the proapoptotic activity of a novel compound targeting Bcl-X(L).

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Pretreatment with AT-101 enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis of breast cancer cells by inducing death receptors 4 and 5 protein levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

The Bcl-2 homology domain 3 mimetic gossypol induces both Beclin 1-dependent and Beclin 1-independent cytoprotective autophagy in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Small inhibitor of Bcl-2, HA14-1, selectively enhanced the apoptotic effect of cisplatin by modulating Bcl-2 family members in MDA-MB-231 breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

An inhibitor of Bcl-2 family proteins induces regression of solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Alteration of the mitochondrial apoptotic pathway is key to acquired paclitaxel resistance and can be reversed by ABT-737.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Displacement of Bim by Bmf and Puma rather than increase in Bim level mediates paclitaxel-induced apoptosis in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

A novel BH3 ligand that selectively targets Mcl-1 reveals that apoptosis can proceed without Mcl-1 degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Deciphering the rules of programmed cell death to improve therapy of cancer and other diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Distinct Genetic and Epigenetic Changes in Medullary Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1136/JCLINPATH-2012-201361

10.1136/JCLINPATH-2012-201361

21 January 2018

Identifiers

DOI

1 reference

28 August 2017

1 reference